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Antibiofilm activity of a nitric oxide generating wound dressing demonstrated. 
 
Prevention and treatment of biofilms shown with 13 species of bacteria and yeasts. 
 
Activity against mixed and single species biofilms including MRSA and MDR strains. 
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Wound bioburden plays an important role in impaired healing and the development of 
infection-related complications. The objective of this study was to determine the efficacy of 
an innovative two-layer nitric oxide generating system (NOx) to prevent and treat biofilms 
formed by bacterial and fungal pathogens commonly associated with wound infection, and 
activity against Pseudomonas aeruginosa virulence factors. Single and mixed species 
biofilms were grown for 24h on nitrocellulose filters placed on agar. Filters were covered 
with either NOx or placebo, before and after biofilm formation. Populations of bacteria and 
yeasts were determined using viable counts. Pyocyanin and elastase production from P. 
aeruginosa were determined in supernatants derived from suspended biofilms. Efficacy of 
NOx was demonstrated against Staphylococcus aureus, P. aeruginosa, Acinetobacter 
baumannii, Escherichia coli and Candida spp. Population reductions between 2 and 10 log 
fold were observed. Pyocyanin and elastase activities from P. aeruginosa were reduced 1.9 
and 3.2-fold respectively. This study demonstrated activity of NOx against formation and 
treatment of single and mixed species biofilms, including multi-drug resistant strains. NOx 
represents a new generation of antimicrobial agent with potent, broad-spectrum activity, and 
with no evidence of resistance development. 
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The microbial burden of acute and chronic wounds plays an important role in impaired 
healing and development of infection-related complications. Prevalence of infection in 
chronic wounds is reported as 53 %
 
[1]. In these patients, inadequate infection management 
can result in lower limb amputation and bloodstream invasion, with complications such as 
sepsis, multi-organ failure and death [2]. Biofilm formation is now thought to exacerbate 
wound infection and delay healing, not only in chronic wounds [3, 4] but also following acute 
injury [5]. By intensifying inflammation, biofilms are heavily implicated in the chronicity 
and delayed healing of venous leg ulcers, pressure ulcers and diabetic foot ulcers [6]. 
Biofilms form when bacterial communities deposit polymeric matrices, serving to store 
nutrients, enhance adherence and protect the cells within the matrix from both the host 
immune response and penetration by antimicrobial agents. Notoriously difficult to eradicate, 
the increased tolerance of biofilm microorganisms to conventional antimicrobial agents, 
compared with their planktonic counterparts [7] poses significant clinical problems. 
Exacerbating the problem is antimicrobial resistance, with the risk of developing chronic 
wounds and the prevalence of antimicrobial resistance rising simultaneously [8]. Of 
particular concern, the resistance to antibiotics of last resort, such as vancomycin and the 
carbapenems, is now well documented [9-11].  
 
For any new wound treatment to be deemed effective, multiple challenges must be overcome. 
This would include showing efficacy against a broad range of wound-associated bacteria, 
including the most commonly isolated, aggressive opportunistic pathogens such as 
Staphylococcus aureus and Pseudomonas aeruginosa [12], biofilms and multidrug-resistant 
(MDR) strains [13]. In certain cases, tolerance to antimicrobials is attributed to ease of 














[14]. Within a biofilm, microbial cells may exhibit altered behaviours, particularly relating to 
growth rate and gene transcription [15,16].
 
Whilst there are now a myriad of antimicrobial 
agents on the market, for prevention and treatment of wound bioburden and infection, 
guidelines currently support their use only after clinical diagnosis of infection [17]. Several 
wound dressings that claim to combat biofilms are currently available but there remains a 
distinct lack of evidence to support the effectiveness of these dressings. Rather, many 
commercial topical agents and wound dressings are acknowledged to be ineffective against 
biofilm infections [18].  
 
NOx has been developed as an advanced wound treatment device, with the added benefit of 
generating nitric oxide in situ. Comprising a non-adherent contact layer, and an absorptive 
hydrogel secondary layer, nitric oxide is generated, with a total amount of approximately 3 
μmoles/cm
2
 of dressing produced over a 48 hour period, as an ancillary function when the 
two layers are placed in contact and applied to the wound. The dressing has undergone all 
International Standard biocompatibility tests, including skin irritation testing, demonstrating 
safety and enabling a phase II/III clinical study on open wounds with no adverse effects 
observed. The dressing provides cushioning, protection and absorption of wound exudate, 
and also aids healing and prevents infection via intrinsic properties of nitric oxide; including 
vasodilation, modulation of the host immune responses and antimicrobial activity [19].  
 
In health, nitric oxide is produced endogenously and is critical in defence against infection 
[19].  Its activities are concentration dependent, where at low concentrations (< 1 μM); it 
promotes growth and activity of host immune cells. While at high concentrations (> 1 μM) it 
acts against multiple targets to inhibit or kill microbial pathogens [20]. In contrast, 














targeting protein synthesis, nucleic acid metabolism or membrane function of 
microorganisms. Importantly, whilst high doses of nitric oxide can kill a wide variety of 
pathogenic bacteria, at low levels it acts as a key mediator of biofilm dispersal, capable of 
rendering detached bacteria sensitive to conventional antimicrobials [20-22]. As an integral 
and highly conserved component of host immunity, it is unsurprising that resistance to nitric 
oxide has yet to be demonstrated [23]. Its inherent broad-spectrum antimicrobial activity 
against protein, lipid and nucleic acid microbial components therefore makes it a promising 
target for clinical development. For planktonic bacteria, minimum inhibitory concentration 
(MIC) tests are the gold standard for determining susceptibility to antimicrobial agents [24]. 
However, for biofilms susceptibility testing is not standardised and many different models are 
used. For studies associated with wound infection, models that generate air/surface biofilms 
are the most appropriate. 
 
We have previously demonstrated a model whereby mature P. aeruginosa biofilms are 
formed after 24 hours, and that biofilm architecture, cell density and gene expression of these 
populations does not alter significantly for a further 24 hours [25, 26]. Using this established 
model, we have tested here the effect of NOx for the prevention and treatment of biofilms 
formed by species of bacteria and yeasts commonly associated with wound infection. 
 
2. Materials and methods 
2.1. Strains and growth conditions 
Bacterial and fungal strains used in this study are listed in Table 1. Gram negative and Gram 
positive bacteria were routinely grown at 37
o
C on LB agar (Invitrogen) and tryptone soya 
agar (TSA; Oxoid), respectively. Candida strains were grown on sabouraud agar (4% 














with 5% CO2 and with agitation (200 rpm) at 37°C in LB broth (Gram –ves), tryptone soya 
broth (TSB) for Gram +ves and sabouraud broth (Oxoid) for Candida. 
 
2.2 Filter biofilm method 
Biofilms were grown on 25-mm diameter nitrocellulose filters (GSWP02500, Millipore) 
placed on agar (20% w/v LB agar, Gram –ves; 20% w/v Mueller Hinton agar, Gram +ves; 
sabouraud agar, Candida spp.), as previously described [25]. For biofilm prevention studies, 
replicate filters were inoculated with 10
5
 colony-forming units (CFU), a population accepted 





species/strain under test and incubated at 37°C for 30 or 60 minutes, as indicated. Filters 
were then covered with either placebo or NOx test mesh squares (5 x 5 cm) followed by the 
NOx hydrogel secondary layer, cut aseptically into 6 x 6 cm squares. Placebo mesh squares, 
NOx test mesh squares and hydrogel secondary layers were obtained from Edixomed Ltd. 
(Edinburgh). After 24 h incubation (37°C), dressings were removed and filters placed into 5 
ml liquid medium (LB broth, Gram –ve; TSB, Gram +ves). To remove micro-organisms the 
resuspended filters were vortexed twice for 30 seconds, and scraped with a sterile loop. To 
enumerate microbial populations, viable counts were performed using solidified agar (LB 
agar, Gram –ve; TSA, Gram +ves; sabouraud, Candida spp.) incubated aerobically (37°C). 
For examination of effect on mature biofilms, inoculated filters were incubated for 24 h 
(37°C) prior to addition of test materials.  
 
2.3 Polymicrobial biofilms 
Filters were inoculated with 10
5
 CFU of both P. aeruginosa PAO1 and MRSA NCTC 12493. 
For quantification of bacterial populations, viable counts were performed using Pseudomonas 
Isolation Agar (PIA; Difco) incubated aerobically overnight (37
o














(Oxoid) containing 5% defibrinated horse blood (TCS Biosciences Ltd., Bucks, UK) 
incubated anaerobically (37
o
C) for 24 h, to select for MRSA. 
 
2.4 Detection of P. aeruginosa virulence factor (VF) production. 
VF assays were performed using culture supernatants generated from mature biofilms grown 
and disrupted as described above. Re-suspended biofilm cells were pelleted by centrifugation 
(4000 rpm, 10 minutes, 4
o
C) and the supernatant sterilised (0.22 µm pore membranes). To 
assess P. aeruginosa elastase production, 250 µl of sterile supernatant from triplicate 
suspensions were screened using the quantitative elastin Congo red (ECR; Sigma) assay as 
previously described [29]. The supernatant pyocyanin content was quantified as previously 
described [30]. 
 
2.5 Statistical analyses 
Differences between placebo and NOx treated conditions were analysed using the Mann 
















3.1 Prevention and treatment of S. aureus biofilms 
Placebo dressings (non NOx-generating) allowed biofilm cell densities to reach between 




 CFU / filter for the S. aureus strains examined. 
However, the NOx device was found to prevent biofilm formation and reduce bacterial 
populations to below detectable levels (50 CFU/Filter) for all strains tested (Fig. 1A). Wound 
dressings (placebo or NOx) were also added 24 h post-inoculation. Biofilm formation was 
then analysed following a further 24 h incubation period. For all test strains, a median 
population of ≥6x10
7
 CFU / filter survived beneath placebo dressings. Below NOx dressings, 
bacterial polymer / cell debris was still observed on the filter surface. However, the surviving 
bacterial population was below detectable levels for MRSA (NCTC 12493) biofilms, and 
showed 6.1 and 2.4 log fold reductions for S. aureus Newman and VISA strain Mu50, 
respectively (Fig. 1B). 
 
3.2 Prevention and treatment of P. aeruginosa and other enteric species biofilms 
Placebo dressings allowed high cell density biofilm formation of P. aeruginosa and other 




 CFU / filter for the 7 strains). 
NOx not only prevented biofilm formation (Fig. 1A), but reduced bacterial populations to 
below detectable levels for the following bacterial strains; P. aeruginosa (PAO1, PA5 & 
PA57), A. baumannii (ATCC 19606 & Ab186) and E. coli (ATCC 25922). NOx also 
prevented biofilm formation (at least 7.7 log fold reduction) for K. pneumoniae (NCTC 





 CFU / filter accumulated beneath placebo dressings. Beneath the NOx dressings, 
bacterial polymer / cell debris was still observed on the filter surface after treatment. 














biofilms (strains PAO1, PA5 & PA57), whilst E. coli (ATCC 25922) and K. pneumoniae 
(NCTC 13368) showed at least 6.2 and 4.8 log fold reductions, respectively. NOx treated A. 
baumannii (ATCC 19606 and Ab186) median populations were reduced 2 to 2.9 log fold 
compared to placebo (Fig. 1B). 
 
3.3 Effect of NOx on virulence factor production from P. aeruginosa 
Mean PA5 strain pyocyanin activity was reduced by 1.9 fold under NOx treated biofilms, 
compared to placebo biofilms. Elastase activity was reduced by 3.2 fold under NOx 
compared to placebo. 
 
3.4 NOx effect on mixed species biofilms 
In biofilm prevention studies, populations of both P. aeruginosa and MRSA beneath NOx 
were below detectable levels (Fig. 2A). In biofilm treatment studies, placebo or NOx was 
added 24 h post-inoculation. NOx reduced both P. aeruginosa (at least 4.1 log fold reduction) 
and MRSA (at least 5.3 log fold reduction) populations compared to untreated biofilms 
(control) and placebo treated samples (Fig. 2B).  
 
3.5 NOx effect on Candida species biofilms 
In biofilm prevention studies, populations of the 3 Candida spp. were below detectable levels 
(Fig. 3A). In biofilm treatment studies, placebo or NOx was added 24 h post-inoculation. 
Median population reductions in the range of 2.1 to 3.9 log fold were observed for Candida 


















This study was designed to evaluate the antimicrobial activity of NOx to prevent and treat 
microbial biofilms. A well characterised anti-biofilm method was used, whereby air-surface 
biofilms were covered with the dressings to be evaluated and after their removal the filters 
could be harvested and bacteria remaining on the filter surface enumerated by quantitative 
bacteriology. This enables the prediction of antimicrobial efficacy at a simulated “wound” 
interface. Importantly, others have used a similar system to demonstrate efficacy of novel 
agents to treat or prevent biofilms produced by bacterial burn wound isolates [31]. 
Inoculation densities were chosen which would be in excess of that reported to normally 
colonise a wound [27].  
 
NOx prevented biofilm formation with all species/strains of bacteria tested, including 
antibiotic sensitive and multidrug resistant strains. These included S. aureus (MSSA, MRSA 
and VISA), P. aeruginosa, A. baumannii, E. coli, K. pneumoniae (including antibiotic 
sensitive and strains resistant to many penicillin and cephalosporin antibiotics) and 3 
Candida species. NOx was also effective in treating established biofilms formed by all strains 
screened. Bacterial populations were eliminated or markedly reduced for Gram positive 
species. Activity against carbapenem resistant bacteria and vancomycin intermediate 
Staphylococcus aureus (VISA) was observed. Similarly, efficacy was demonstrated against 
P. aeruginosa, antibiotic sensitive and MDR; A. baumannii, antibiotic sensitive and MDR; E. 
coli, antibiotic sensitive; K. pneumoniae (resistant to many penicillin and cephalosporin 
antibiotics). Importantly, efficacy against MRSA / P. aeruginosa dual species biofilms was 
demonstrated. This is a crucial finding as it is usual for wounds to be colonised by more than 















Virulence factors from P. aeruginosa that aid in the resistance to host immune responses and 
may be associated with the prevention of wound repair were reduced as a consequence of 
biofilm disruption by NOx.  Both pyocyanin and elastase were reduced in established P. 
aeruginosa biofilms.  This may have important implications for clinical application, through 
the reduction of factors known to cause tissue damage [29]. In addition to the reduction in 
biofilm bioburden, it is suggested that NOx might facilitate healing of wounds with 
established P. aeruginosa infections, through the reduction of factors that cause persistence 
of infection and tissue damage.  
 
The most resistant biofilms were formed by A. baumanni, where bacterial populations were 
not completely eradicated; high cell density biofilms were observed to re-form after removal 
of the dressing. This suggests that repeat exposures might be needed to eradicate biofilm 
populations if they are not completely cleared upon a single exposure to NOx. However, 
significant reductions in vivo may allow the host immune response to overcome the infection. 
Subsequently, repeat exposure tests confirmed that mature A. baumanni biofilms were 
eradicated after two exposures to NOx (Waite & Allaker, unpublished observations). This 
suggests that replacement of fresh NOx dressing is sufficient to eradicate mature biofilms 
whose bacterial population are not cleared in a single exposure.  
 
In terms of any proposed mechanism, Barraud et al suggested that in addition to killing 
bacterial cells, nitric oxide at sub-bactericidal concentrations is able to penetrate biofilm 
matrices and initiate cell dispersion [21, 22]. This ability to disperse bacteria from a biofilm 
is promising, in that once bacterial cells have re-entered the planktonic state, they are more 
susceptible to standard antimicrobial agents than in their biofilm state. Hetrick et al [32]
 














them permeable to propidium iodide staining, and further suggested that rapid delivery of 
nitric oxide  may be more effective at biofilm killing than slow/ prolonged delivery. Both of 
these authors suggest that greater levels of nitric oxide released over short durations are more 
damaging, particularly to Gram-negative bacteria, than sustained, lower-level surface fluxes. 
The double lipid bilayer of Gram-negative bacteria typically acts as a permeability barrier to 
antibiotics that function within the cell. Ironically, it is this same structural characteristic that 
renders these cells particularly susceptible to nitric oxide- induced membrane damage [33].  
 
In the normal biofilm cycle, nitric oxide production coincides with cell death and dispersal, 
as part of a co-ordinated process of solubilisation and chemotaxis. Introducing low, non-toxic 
doses of nitric oxide to biofilms, in the picomolar to nanomolar range, mimics this process, 
triggering dispersal and the transition back to the planktonic state of growth. Additionally, 
nitric oxide restores the sensitivity of biofilm and dispersed bacteria towards several classes 
of antimicrobial agents, restoring their efficacy [22]. In their recent examination of transition 
in wound biofilms of the diabetic foot, Loesche et al. [34] concluded that instability of the 
wound microbiota leads to faster healing and improved repair. Any agent capable of 
physically and chemically disrupting a biofilm would therefore be a welcome addition to the 
dressing armoury. 
 
NOx represents a new wound treatment system which has, as an ancillary aid to its wound 
healing properties, the rapid generation of nitric oxide. This current series of studies has 
demonstrated efficacy of the NOx treatment system against a wide variety of wound 
microbes, both antibiotic sensitive and resistant. It is the hope that this may translate to 
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Figure 1 Effect of NOx on prevention of single species biofilm formation (A) and on 
treatment of pre-formed single species biofilms (B). Bars signify the median for biofilms 
(n=4, except PA01 in triplicate) with error bars showing range. All strains analysed showed 


















Figure 2 Effect of NOx on prevention of MRSA / P. aeruginosa dual species biofilm 
establishment (A) and treatment of pre-formed dual species biofilms (B). Bars signify the 

















Figure 3 Effect of NOx on prevention (A) and treatment of pre-formed (B) Candida spp. 
















Table 1. Microbial strains 
Organism Strain name Characteristics Notes 
P.  aeruginosa PAO1 Antibiotic sensitive wound 
isolate 
 
PA5 Wound isolate, MDR, 
harbours the TEM β-
lactamase. 
MDR (multiple drug 
resistance) 
PA57 Pus isolate with VIM-2 MDR, Carbapenem 
resistant 
A. baumannii ATCC 19606 Antibiotic sensitive isolate  




E.  coli ATCC 25922 Antibiotic sensitive isolate  
K. pneumoniae NCTC 13368 Extended spectrum β-
lactamase (ESBL) producer 
(SHV-18) 
ESBL producer - resistant 
to many penicillin and 
cephalosporin antibiotics 
S. aureus  Newman Antibiotic sensitive human 
isolate. Methicillin-sensitive 
S. aureus (MSSA). 
 
Methicillin-resistant S. 
aureus (MRSA)  
NCTC 12493 mecA MDR 
Vancomycin-intermediate S. 
aureus (VISA)  
Mu50 vraSR MDR 
Candida albicans ATCC 24433   
Candida krusei  ATCC 750   
Candida tropicalis ATCC 6258   
 
 
 
